help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0361
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/8/3165    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pagano, C.
Right arrow Articles by Vettor, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pagano, C.
Right arrow Articles by Vettor, R.
Related Collections
Right arrow Obesity
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 8 3165-3170
Copyright © 2006 by The Endocrine Society

Reduced Plasma Visfatin/Pre-B Cell Colony-Enhancing Factor in Obesity Is Not Related to Insulin Resistance in Humans

Claudio Pagano, Catia Pilon, Massimiliano Olivieri, Paola Mason, Roberto Fabris, Roberto Serra, Gabriella Milan, Marco Rossato, Giovanni Federspil and Roberto Vettor

Endocrine-Metabolic Laboratory, Department of Medical and Surgical Sciences, University of Padua, 35100 Padua, Italy

Address all correspondence and requests for reprints to: Claudio Pagano, M.D., Ph.D., Department of Medical and Surgical Sciences, University of Padova, Via ospedale 105, 35100 Padova, Italy. E-mail: claudio.pagano{at}unipd.it.

Context: Visfatin was recently identified as a protein highly expressed and secreted in adipose tissue with insulin-mimetic effect and is a candidate hormone to help explain the association among adipose tissue expansion, insulin resistance, and type 2 diabetes.

Objective: The objective of the study was to assess expression of visfatin in lean and obese subjects and in sc and visceral adipose tissue and moreover to explore the role of visfatin on insulin resistance in humans.

Design: We measured circulating visfatin and its mRNA expression in sc adipose tissue (SAT) in lean and obese subjects. Furthermore, we measured visfatin mRNA in visceral adipose (VAT) and SAT by quantitative RT-PCR. Finally, plasma visfatin and its mRNA in SAT were measured under free fatty acid-induced insulin resistance in healthy subjects.

Results: Plasma visfatin and its mRNA in SAT were significantly lower in obese subjects, compared with normal-weight controls. Both circulating visfatin and SAT visfatin mRNA were negatively correlated with body mass index, whereas no correlation was found with homeostasis model assessment. Significantly higher visfatin mRNA was found in VAT of obese subjects, compared with lean controls. Interestingly, visfatin mRNA in VAT was positively correlated with BMI. Elevation of free fatty acid induced a condition of insulin resistance but did not affect either circulating visfatin or its mRNA.

Conclusions: Our findings show that, in human obesity, plasma visfatin is reduced, whereas visfatin mRNA is differentially regulated in SAT and VAT. Visfatin is not related to insulin resistance either as assessed by homeostasis model assessment or during lipid infusion.




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
T. Luk, Z. Malam, and J. C. Marshall
Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity
J. Leukoc. Biol., April 1, 2008; 83(4): 804 - 816.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Korner, A. Garten, M. Bluher, R. Tauscher, J. Kratzsch, and W. Kiess
Molecular Characteristics of Serum Visfatin and Differential Detection by Immunoassays
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4783 - 4791.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
K M Choi, J H Kim, G J Cho, S H Baik, H S Park, and S M Kim
Effect of exercise training on plasma visfatin and eotaxin levels
Eur. J. Endocrinol., October 1, 2007; 157(4): 437 - 442.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
G. Mastorakos, G. Valsamakis, D. C. Papatheodorou, I. Barlas, A. Margeli, A. Boutsiadis, E. Kouskouni, N. Vitoratos, A. Papadimitriou, I. Papassotiriou, et al.
The Role of Adipocytokines in Insulin Resistance in Normal Pregnancy: Visfatin Concentrations in Early Pregnancy Predict Insulin Sensitivity
Clin. Chem., August 1, 2007; 53(8): 1477 - 1483.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. M. de Souza Batista, R.-Z. Yang, M.-J. Lee, N. M. Glynn, D.-Z. Yu, J. Pray, K. Ndubuizu, S. Patil, A. Schwartz, M. Kligman, et al.
Omentin Plasma Levels and Gene Expression Are Decreased in Obesity
Diabetes, June 1, 2007; 56(6): 1655 - 1661.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
E. Ingelsson, M. G. Larson, C. S. Fox, X. Yin, T. J. Wang, I. Lipinska, K. M. Pou, U. Hoffmann, E. J. Benjamin, J. F. Keaney Jr., et al.
Clinical Correlates of Circulating Visfatin Levels in a Community-Based Sample
Diabetes Care, May 1, 2007; 30(5): 1278 - 1280.
[Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
G. Sun, J. Bishop, S. Khalili, S. Vasdev, V. Gill, D. Pace, D. Fitzpatrick, E. Randell, Y.-G. Xie, and H. Zhang
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men
Am. J. Clinical Nutrition, February 1, 2007; 85(2): 399 - 404.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. J. Walley, A. I.F. Blakemore, and P. Froguel
Genetics of obesity and the prediction of risk for health
Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R124 - R130.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Lopez-Bermejo, B. Chico-Julia, M. Fernandez-Balsells, M. Recasens, E. Esteve, R. Casamitjana, W. Ricart, and J.-M. Fernandez-Real
Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Diabetes, October 1, 2006; 55(10): 2871 - 2875.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society